Advertisement

Volume 3, Issue 5

 

Cover Image

Cover Figure: Immunofluorescence microscopy of lymph node sections stained with anti-CD4, anti-FoxP3, and anti-RORγt demonstrating the functional polarization of tonsillar CD4+ T cells. See the article by Mamand et al.

WASHINGTON, March 12, 2019 – Welcome to the “Advance Notice,”  newsletter which provides highlights from issues of Blood Advances, the open-access journal of the American Society of Hematology (ASH), that  are hand-picked by Blood Advances Editor-in-Chief Robert Negrin, MD.

 

In their Stimulus Report, Varelias et al demonstrate that granulocyte colony-stimulating factor (G-CSF) promotes interleukin-17A secretion by CD8+ mucosa-associated invariant T cells, which have been associated with chronic graft-versus-host disease (GVHD) in other studies. This is an important finding. In the current landscape, mobilization reagents other than G-CSF are available. It is imperative to know which reagent mobilizes the optimal stem cell product for survival, graft-versus-leukemia, and protection from GVHD after transplant.

 

 


Featured Visual Abstracts

Oncolytic immunotherapy and bortezomib synergy improves survival of refractory multiple myeloma in a preclinical model

Chandini M. Thirukkumaran, Zhong Qiao Shi, Gerard J. Nuovo, Joanne Luider, Karen A. Kopciuk, Yuan Dong, Ahmed A. Mostafa, Satbir Thakur, Kathy Gratton, Ailian Yang, Alex C. Chin, Matt C. Coffey, Victor H. Jimenez-Zepeda, Douglas Stewart, Marta Chesi, P. Leif Bergsagel and Don Morris

 

 

 

 

Enhancing the antitumor functions of invariant natural killer T cells using a soluble CD1d-CD19 fusion protein

Rupali Das, Peng Guan, Susan J. Wiener, Nishant P. Patel, Trevor G. Gohl, Elizabeth Evans, Maurice Zauderer and Kim E. Nichols

 

 

 

 

 

 

 

 

 

 

 

 

Blood Advances is the open-access journal of the American Society of Hematology (ASH) (www.hematology.org), the world’s largest professional society concerned with the causes and treatment of blood disorders.

ASH’s mission is to further the understanding, diagnosis, treatment, and prevention of disorders affecting blood, bone marrow, and the immunologic, hemostatic, and vascular systems by promoting research, clinical care, education, training, and advocacy in hematology.